Biogen Leans On Pipeline As Tecfidera, Spinraza See Q4 Sales Dip

Aducanumab Added To 2021 Guidance Amid Approval Optimism

 
• By Alaric DeArment
  
Generate a summary of this article
Listen to this article
Beta

The company sees aducanumab adding a modest boost to sales if approved, but there are another four Phase III programs with some major read-outs coming.

Alzheimers_677117191_Atthapon-Raksthaput_1200.jpg
Biogen leans on aducanumab and other pipeline drugs as sales of Tecfidera and Spinraza slumped in Q4 and 2020. • Source: Shutterstock

Notwithstanding a three-month delay in a US Food and Drug Administration verdict, Biogen, Inc. is including the Alzheimer’s disease drug aducanumab in its 2021 guidance as dampened sales of its approved multiple sclerosis (MS) and spinal muscular atrophy (SMA) drugs have weighed on revenues. And if the amyloid-beta-targeting drug is not approved, the company maintains it still has a deep pipeline beyond aducanumab.

The Cambridge, Massachusetts-based company announced its fourth quarter and full year 2020 earnings on 3 February, announcing fourth quarter revenues...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

Test Roche Head Of Pharma Strategy Karsten Jung On Rebuilding The Portfolio

 
• By Jessica Merrill

The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Reed Miller

In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.

Article Without An Author Listed

Here is a short description.

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains